Outcome of the Board Meeting - May 4, 2026
TATACHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.7 pts less than Nifty Smallcap 250 and 1.3 pts less than its Commodity Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Tata Chemicals reported a consolidated net loss of ₹1,715 crore for FY2026, a sharp reversal from a profit of ₹387 crore in FY2025, driven primarily by a ₹1,837 crore goodwill impairment charge on its US operations due to adverse market conditions and geopolitical factors. Revenue from operations declined marginally to ₹14,584 crore from ₹14,887 crore. The Basic Chemistry segment bore a loss of ₹1,311 crore due to the impairment, while EBITDA margin compressed to 4.14% from 5.58% in the prior year. Exceptional items net totaled ₹1,956 crore, including ₹65 crore additional costs from the UK Lostock plant closure and ₹54 crore from new Indian labour codes. The Board recommended a dividend of ₹11 per share (110%), unchanged from the prior year. Statutory auditors BSR & Co. LLP issued an unmodified opinion. The company has a net worth of ₹22,175 crore and total debt of ₹8,001 crore (Debt-Equity 0.36x).
The large goodwill impairment and operating loss signal stress in the US business and legacy UK operations, though the underlying operating performance excluding one-time items remains under pressure. The unchanged dividend provides some comfort to shareholders despite the loss-making year.